Nitrobenzocyclophosphamides as potential prodrugs for bioreductive activation: Synthesis, stability, enzymatic reduction, and antiproliferative activity in cell culture

Bioorganic and Medicinal Chemistry

Volumn 11, Issue 19, 2003, Pages 4171-4178

  Li, Zhuorong ^a,c   Han, Jiye ^a   Jiang, Yongying ^a   Browne, Patrick ^b   Knox, Richard J ^b   Hu, Longqin ^a  

^a RUTGERS UNIVERSITY   (United States)

^b Enact Pharma PLC   (United Kingdom)

^c INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

7 NITRO 2 [BIS(2 CHLOROETHYL)AMINO] 1,3,2 BENZODIAZAPHOSPHORINANE 2 OXIDE; 7 NITRO 2 [BIS(2 CHLOROETHYL)AMINO] 1,3,2 BENZODIOXAPHOSPHORINANE 2 OXIDE; 7 NITRO 2 [BIS(2 CHLOROETHYL)AMINO] 1,3,2 BENZOXAZAPHOSPHORINANE 2 OXIDE; 7 NITRO 2 [BIS(2 CHLOROETHYL)AMINO] 3,1,2 BENZOXAZAPHOSPHORINANE 2 OXIDE; ANTINEOPLASTIC AGENT; BENZYL DERIVATIVE; BENZYLIC CARBON; BENZYLIC OXYGEN; BUFFER; CYCLOPHOSPHAMIDE; NITRO DERIVATIVE; NITROREDUCTASE; PHOSPHATE; PRODRUG; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER GENETICS; CELL CULTURE; CELL PROLIFERATION; CYTOTOXICITY; DRUG ACTIVITY; DRUG DESIGN; DRUG HALF LIFE; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME SUBSTRATE; ESCHERICHIA COLI; GENE THERAPY; NONHUMAN; PH; PROTEIN EXPRESSION; REDUCTION; TEMPERATURE;

ESCHERICHIA COLI;

EID: 0042890380     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(03)00459-0     Document Type: Article

References (26)

1. Zon G. Prog. Med. Chem. 19:1982;205.
2. Stec W.J. J. Organophosphorous Chem. 13:1982;145.
3. Borch R.F., Millard J.A. J. Med. Chem. 30:1987;427.
4. Hilton J. Cancer Res. 44:1984;5156.
5. Cox P.J. Biochem. Pharmacol. 28:1979;2045.
6. Wright J.E. Teicher B.A. Cancer Therapeutics: Experimental and Clinical Agents. 1997;23-79 Humana Press Inc, Totowa, NJ.
7. Arnold H., Bourseaux F., Brock N. Nature. 181:1958;931.
8. Pochopin N.L., Charman W.N., Stella V.J. Int. J. Pharmaceut. 121:1995;157.
9. Oliyai R., Stella V.J. Annu. Rev. Pharmacol. Toxicol. 32:1993;521.
10. Bundgaard H. Design of Prodrugs. 1985;Elsevier, Amsterdam.
11. McNeish I.A., Searle P.F., Young L.S., Kerr D.J. Adv. Drug Deliv. Rev. 26:1997;173.
12. Niculescu-Duvaz I., Springer C.J. Adv. Drug Deliv. Rev. 26:1997;151.
13. Senter P.D., Svensson H.P. Adv. Drug Deliv. Rev. 22:1996;341.
14. Sherwood R.F. Adv. Drug Deliv. Rev. 22:1996;269.
15. Springer C.J., Niculescu-Duvaz I. Adv. Drug Deliv. Rev. 22:1996;351.
16. Bridgewater J., Minton N.P., Michael N.P., Knox R., Springer C., Collins M. Eur. J. Cancer. 31:1995;2362.
17. Anlezark G.M., Melton R.G., Sherwood R.F., Coles B., Friedlos F., Knox R.J. Biochem. Pharmacol. 44:1992;2289.
18. Knox R.J., Friedlos F., Sherwood R.F., Melton R.G., Anlezark G.M. Biochem. Pharmacol. 44:1992;2297.
19. Ludeman S.M., Zon G. J. Med. Chem. 18:1975;1251.
20. Takamizawa A., Matsumoto S. Chem. Pharm. Bull. 26:1978;790.
21. Shih Y.-E., Wang J.-S., Chen C.-T. Hetercycles. 9:1978;1277.
22. Borch R.F., Canute G.W. J. Med. Chem. 34:1991;3044.
23. Viljanen T., Tahtinen P., Pihlaja K., Fulop F. J. Org. Chem. 63:1998;618.
24. Hu L., Liu B., Hacking D.R. Bioorg. Med. Chem. Lett. 10:2000;797.
25. Melton R.G., Knox R.J. Enzyme-prodrug Strategies for Cancer Therapy. 1999;Kluwer Academic/Plenum, New York.
26. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Warren J.T., Bokesch H., Kenney S., Boyd M.R. J. Natl. Cancer Inst. 82:1990;1107.